Human regulatory T cells in allogeneic stem cell transplantation.

GVHD is still one of the major complications after allogeneic stem cell transplantation. Whereas murine data have clearly shown the beneficial effects of regulatory T cells (Tregs) on the prevention of GVHD, data from the human system are rare. Here, we present a comparative dynamic analysis of CD4(+)CD25(hi)CD127(lo/-) Tregs from patients with and without GVHD analyzing the whole genome profile over the first 6 months after stem cell transplantation, representing the most sensitive time window for tolerance induction. The Treg transcriptome showed a high stability. However, the comparison of Treg transcriptomes from patients with and without GVHD uncovered regulated gene transcripts highly relevant for Treg cell function. The confirmative protein analyses demonstrated a significantly higher expression of granzyme A, CXCR3, and CCR5 in Tregs of immune tolerant patients. These results point to a reduced suppressive function of Tregs from GVHD patients with diminished migration capacity to the target organs.

[1]  B. Puisac,et al.  Cornelia de Lange syndrome with NIPBL mutation and mosaic Turner syndrome in the same individual , 2012, BMC Medical Genetics.

[2]  B. Falini,et al.  Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. , 2011, Blood.

[3]  J. Wagner,et al.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.

[4]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[5]  D. Hafler,et al.  FOXP3+ regulatory T cells in the human immune system , 2010, Nature Reviews Immunology.

[6]  T. Ley,et al.  Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. , 2010, Blood.

[7]  A. Chopra,et al.  CD44 expression positively correlates with Foxp3 expression and suppressive function of CD4+ Treg cells , 2009, Biology Direct.

[8]  E. Shevach.  Mechanisms of foxp3+ T regulatory cell-mediated suppression. , 2009, Immunity.

[9]  Alf Hamann,et al.  Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? , 2009, Nature Reviews Immunology.

[10]  Fabian Model,et al.  Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. , 2009, Cancer research.

[11]  Satoshi Takahashi,et al.  Gene-expression profiles of peripheral blood mononuclear cell subpopulations in acute graft-vs-host disease following cord blood transplantation. , 2008, Experimental hematology.

[12]  Sonja Vorwerk,et al.  Microfluidic-based enzymatic on-chip labeling of miRNAs. , 2008, New biotechnology.

[13]  S. Oh,et al.  Cell cycle and immune-related processes are significantly altered in chronic GVHD , 2008, Bone Marrow Transplantation.

[14]  T. Miyazaki,et al.  Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model , 2008, Gene Therapy.

[15]  F. Gunzer,et al.  Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity , 2007, PloS one.

[16]  K. Rezvani,et al.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. , 2007, Blood.

[17]  G. Nepom,et al.  Cutting Edge: High Molecular Weight Hyaluronan Promotes the Suppressive Effects of CD4+CD25+ Regulatory T Cells1 , 2007, The Journal of Immunology.

[18]  K. Rezvani,et al.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. , 2006, Blood.

[19]  E. Thiel,et al.  Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. , 2006, Blood.

[20]  M. Siegelman,et al.  Suppressor activity and potency among regulatory T cells is discriminated by functionally active CD44. , 2006, Blood.

[21]  R. Geffers,et al.  The host response to the probiotic Escherichia coli strain Nissle 1917: Specific up-regulation of the proinflammatory chemokine MCP-1 , 2005, BMC Medical Genetics.

[22]  J. Serody,et al.  Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. , 2005, Blood.

[23]  J. Ritz,et al.  Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. , 2005, Blood.

[24]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Martínez-A,et al.  CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. , 2005, Blood.

[26]  M. Remberger,et al.  Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  S. Sakaguchi.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.

[28]  Matthias Edinger,et al.  Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. , 2005, Blood.

[29]  J. Serody,et al.  L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. , 2004, Blood.

[30]  T. Ley,et al.  Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. , 2004, Blood.

[31]  M. Shlomchik,et al.  Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. , 2004, Blood.

[32]  J. Serody,et al.  Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning1 , 2004, The Journal of Immunology.

[33]  M. Anver,et al.  An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. , 2004, Experimental hematology.

[34]  J. Buer,et al.  Developmental Stage, Phenotype, and Migration Distinguish Naive- and Effector/Memory-like CD4+ Regulatory T Cells , 2004, The Journal of experimental medicine.

[35]  M. Territo,et al.  Amelioration of graft versus host disease by galectin-1. , 2003, Clinical immunology.

[36]  S. Clouthier,et al.  Role of CXCR3-induced donor T-cell migration in acute GVHD. , 2003, Experimental hematology.

[37]  David E. Misek,et al.  Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. , 2003, Blood.

[38]  P. Bird,et al.  The Intracellular Granzyme B Inhibitor, Proteinase Inhibitor 9, Is Up-Regulated During Accessory Cell Maturation and Effector Cell Degranulation, and Its Overexpression Enhances CTL Potency1 , 2003, The Journal of Immunology.

[39]  C. Fathman,et al.  Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.

[40]  David Klatzmann,et al.  CD4+CD25+ Immunoregulatory T Cells , 2002, The Journal of experimental medicine.

[41]  Stefano Iacobelli,et al.  Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? , 2002, Trends in immunology.

[42]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[43]  L. Baum,et al.  Apoptosis of T cells mediated by galectin-1 , 1995, Nature.

[44]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[45]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.